effects. Moreover, whether genetic models of marked obesity (10, 11) exhibit cardiomyocyte apoptosis independent of conventional risk factors such as hypertension or diabetes mellitus, is uncertain. (12) (13) (14) (15) We have recently developed an animal model of dietary-induced obesity without increases in blood pressure and with a normal blood glucose control, (16) but, in the present study we evaluated whether this animal model is associated with excessive cardiomyocyte apoptosis. Obesity is a risk factor for heart failure; (1) (2) (3) heart failure is associated with excessive adrenergic activation; 
INTRODUCTION
Obesity is a risk factor for heart failure independent of other conventional cardiovascular risk factors. (1) (2) (3) As adjustments for cardiac systolic chamber function abolish the relationship between obesity and heart failure (2) it is possible that heart failure in obesity is caused by pump dysfunction rather than diastolic abnormalities. There is increasing evidence from both human (4, 5) and animal (6) (7) (8) (9) studies that obesity is associated with myocardial contractile disturbances. These contractile disturbances may occur in even mild-to-moderate forms of excess adiposity. (4, 5) However, the mechanisms responsible for this effect remain uncertain.
An increased cardiomyocyte apoptosis occurs in genetic animal models of marked obesity (10, 11) -an effect that may in part contribute toward obesity associated reductions in myocardial contractile function. However, data obtained in genetic models of marked obesity may not be representative of the more common forms of mild-to-moderate obesity that are induced by dietary and adrenergic activation is a well-recognised stimulus for cardiomyocyte apoptosis; (18) we therefore also explored the possibility that dietary-induced obesity increases the susceptibility of the myocardium to ␤-adrenergic agonist-induced cardiomyocyte apoptosis.
METHODS

Study groups
The present study was approved by the University of the (18) (Diet-ISO, n=14; Control-ISO, n=14) or the saline vehicle (DietSaline, n=16; Control-Saline, n=16). Isoproterenol was constituted in sterile saline (0.9% NaCl) in order that each rat would receive subcutaneous injections of ~0.1-0.2 ml volumes daily. Control rats received daily injections of sterile saline at the same volume.
Blood pressures, blood glucose control and assessment of adiposity Non-invasive tail cuff blood pressures (15) were measured at the beginning and at the end of the study in all rats to confi rm the previously described lack of effect of the experimental diet on blood pressure. (16) The percentage glycosylated haemoglobin (HbA 1c ) was determined to confi rm the previously described normal blood glucose control in the experimental diet fed rats. (16) HbA 1c was determined in blood samples obtained from the thoracic cavity immediately after extirpation of the heart, using the HBA1CII Tina-Quant kit (Cobas-Roche Diagnostics). Body weights were recorded in rats before the start of feeding and then once a month at the same time on the same day of each week until the end of the study. At the end of the study, visceral fat weight was determined post-mortem. To weigh visceral fat, fat was removed from the retroperitoneal space on the posterior wall of the abdominal cavity and from the omentum.
Echocardiography
At the end of the study left ventricular systolic function and chamber dimensions were determined in vivo as previously described (19) in anaesthetised rats (50 mg/kg of ketamine and 3 mg/ kg of xylazine) before and 15 minutes after an acute injection of fi brosis in less than or more than 20% of the fi eld respectively; 3 and 4, diffuse contiguous subendocardial fi brosis in less than or more than 50% of the fi eld respectively and 5 and 6, full thickness fi brosis in less than or more than 50% of the fi eld respectively. (20) The degree of apoptosis was quantifi ed as previously described (18, 21) on 5 μm thick myocardial tissue sections obtained from the same tissue blocks used to assess the pathological score.
Nuclear deoxyribonucleic acid (DNA) fragments in the tissue sections were detected using a non-radioactive in situ apoptotic cell death detection kit (DeadEnd TM Colorimetric TUNEL system, Promega, Madison, WI, USA), where terminal deoxynucleotidyl transferase (TdT) was used to incorporate biotinylated nucleotide at the 3'-OH DNA ends. The number of apoptotic cardiomyocyte nuclei and the total number of cardiomyocyte nuclei (haematoxylin and eosin stain) in each slide were counted on ten evenly spaced fi elds from the apex to the base using a computer-based image acquisition and analysis system at 400 times magnifi cation (Axiovision 3, Carl Zeiss, Gottingen, Germany). Apoptotic cardiomyocyte nuclei were expressed as a percentage of the total number of cardiomyocyte nuclei.
Data analysis
All data are presented as mean±SEM. Comparisons between groups were made with a two-way ANOVA or with a Student's t-test when pooled analysis was performed. Figure 1 shows the effect of the experimental diet on body weight.
RESULTS
Measures of excess adiposity
The experimental diet resulted in a 15% increase in body weight and a 74% increase in visceral fat weight (Control diet=19.6±0.8 g, Experimental diet=33.0±1.2 g, p<0.0001) as compared to control diet fed rats. The body weight in rats receiving the experimental diet was statistically greater than the body weight in rats receiving the control diet, from the fourth month of the study (Figure 1 ).
Importantly, similar dietary effects on body weight and visceral fat were noted in rats assigned to receive either isoproterenol or the vehicle at the end of the study period (data not shown).
Blood pressures and percentage glycosylated haemoglobin
Dietary-induced obesity had no effect on tail-cuff systolic blood pressure (Experimental diet: Baseline=116±3 mm Hg: After 5 months of the study=118±4 mm Hg; Control diet: Baseline=112 ±4 mm Hg: After 5 months of the study=119±4 mm Hg).
In addition, the obesity-inducing diet did not infl uence the percen-
Impact of obesity and short-term adrenergic stimulation on heart weight
As compared to the control diet fed groups a trend for an increase in heart weight and left ventricular weight was noted in the experimental diet fed groups (Table 1) . In a pooled analysis of all control diet fed as compared to all experimental diet fed rats, the experimental diet resulted in an increase in heart weight (Experimental diet=1.23±0. groups as compared to their respective control groups (Table 1) .
Moreover, isoproterenol failed to modify heart weight or left ventricular weight in pooled analysis comparing data obtained in all rats receiving isoproterenol versus all rats receiving the vehicle (data not shown). In a comparison of the four groups, left ventricular weight was greater in the experimental diet group receiving isoproterenol as compared to the two control diet fed groups (Table 1) . As the experimental diet resulted in a greater increase in body weight (~15%) as compared to heart (~8%) or left ventricular weight (~7%) a decrease in the heart and left ventri-OBESITY AND MYOCARDIAL APOPTOSIS Impact of obesity and isoproterenol on cardiomyocyte apoptosis and fi brosis Importantly, neither the experimental diet nor isoproterenol affected the myocardial pathological score. Only minimal fi brosis (ranging from grades 0 to 3) was noted in each of the groups.
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DISCUSSION
The main fi nding of the present study is that the myocardium of obese rats is more sensitive to the myocardial apoptotic effects Previous studies have demonstrated that an increased cardiomyocyte apoptosis accompanies severe obesity in genetic animal models. (10, 11) In this regard, the present study supports the notion that obesity may promote cardiomyocyte apoptotic effects even in mild-to-moderate forms of obesity, albeit that this effect is only noted in the presence of an adrenergic stimulus. In the present study, the lack of ability of obesity per se to promote excessive cardiomyocyte apoptosis in the absence of an adrenergic stimulus may be accounted for by the relatively modest increase in body weight produced by the model studied (body weights ~15% greater than lean animals). This is in contrast to previous studies reporting on obesity-induced effects on cardiomyocyte apoptosis in the absence of an exogenous stimulus such as a ␤-adrenoceptor agonist (10, 11) in genetic rodent models of obesity associated with considerably greater increases in body weights (~45 to 84% greater than lean animals) (11, 22) than those reported on by us. In this regard however, the present study is more likely to refl ect the predominant form of obesity that occurs at a population level (mild-to-moderate) in contrast to previous animal studies that are more likely to refl ect the impact of more severe forms of obesity on the myocardium. (10, 11) In contrast to previous studies (10, 11) where it is uncertain whether the obesity-associated cardiomyocyte apoptotic effect occurs independently of alternative conventional risk factors such as hypertension or diabetes mellitus, (12) (13) (14) (15) in the present study we
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show that obesity is associated with adrenergic-induced cardiomyocyte apoptosis in a model without increases in blood pressure or alterations in blood glucose control (glycosylated haemoglobin) and in a model which we have previously reported to be euglycaemic. (16) Thus, the present study is the fi rst to show that mild-to-moderate adiposity promotes cardiomyocyte apoptosis independent of blood pressure or blood glucose control.
Importantly, however, this effect requires excessive adrenergic activation, a change that often accompanies obesity. (23) In the present study the mechanisms of the increased susceptibility of the myocardium in obese rats to adrenergic-induced cardiomyocyte apoptosis were not identifi ed. However, a few possibilities were considered. First, as the degree of obesity produced in rats in the present study promoted mild increases in left ventricular mass, it is possible that cardiac hypertrophy, which is a well-recognised risk factor for cardiomyocyte apoptosis, (24) can explain the obesity-associated increase in adrenergic-induced cardiomyocyte apoptosis. Second, increases in myocardial reactive oxygen species, previously shown to mediate cardiomyocyte apoptosis (25) and produced by increments in cardiac wall stress need to be considered. In this regard, although we did not measure myocardial wall stress, it is unlikely that this mechanism plays a signifi cant role, as resting systolic blood pressures and left ventricular chamber dimensions were unchanged, and adrenergic-induced inotropic and chronotropic responses in obese rats were comparable to those of lean rats. However, as myocardial ␤-adrenergic stimulation promotes the generation of reactive oxygen species, (26) further studies are required to assess whether obese rat hearts are more susceptible to adrenergicinduced increases in the production or effects of reactive oxygen species. Importantly, it is unlikely that the increased adrenergicinduced cardiomyocyte apoptosis in obese rats can be explained by a combination of exogenous adrenergic actions and increased endogenous sympathetic effects, as this model of obesity is not associated with increases in endogenous norepinephrine release. (16) Third, in genetic animal models, obesity-induced cardiomyocyte apoptosis may also be mediated by the accumulation of triglycerides in the heart. (11) In this regard, a combination of peripheral lipolysis induced by catecholamines and a decrease in the expression of myocardial enzymes responsible for fatty acid oxidation is thought to produce this effect. (11) It is therefore possible that in the present study, obesity promoted a reduction in myocardial fatty acid oxidation, whilst the exogenous adrenergic stimulus produced lipolysis, the overall effect being an increase in cardiomyocyte apoptosis. Further work is required to explore this possibility.
Although caution should be exercised in translating these data to the clinical scenario, some possible clinical implications can be considered. As obesity is a risk factor for heart failure (1) (2) (3) and heart failure is associated with excessive adrenergic activation (17) it is important to consider the combination of these effects.
The present data suggest that this combination mediates a synergistic effect to promote cardiomyocyte apoptosis. As cardiomyocyte apoptosis may have a causal role to play in the pathophysiology of ventricular dysfunction and its progression to cardiac failure, (27, 28) the present data suggest that myocardial decompensation in obese patients with heart failure may progress more rapidly than in lean patients unless appropriate adrenergic blockade is employed.
The limitations of the present study are as follows. In conclusion, the results of the present study indicate that mildto-moderate obesity is associated with an increased susceptibility of the myocardium to adrenergic-induced cardiomyocyte apoptosis independent of changes in blood pressure, left ventricular dilatation or alterations in adrenergic-induced inotropic and chronotropic responsiveness. These fi ndings cast further light on the mechanisms that may explain the independent relationship between obesity and the development of heart failure (1) (2) (3) and suggest that obesity may hasten the progression of cardiac decompensation in heart failure unless appropriate adrenergic blockade is employed. Clinical studies are required, conducted in obese and lean patients with comparable degrees of cardiac dysfunction and sympathetic activation at baseline, to address this issue.
